Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $2.83 in the last session, down -8.71% from day before closing price of $3.10. In other words, the price has decreased by -$8.71 from its previous closing price. On the day, 1.24 million shares were traded. ZNTL stock price reached its highest trading level at $3.1 during the session, while it also had its lowest trading level at $2.82.
Ratios:
We take a closer look at ZNTL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.59 and its Current Ratio is at 6.59. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 04 ’24 when Vultaggio Vincent sold 1,603 shares for $3.18 per share. The transaction valued at 5,098 led to the insider holds 33,855 shares of the business.
Gallagher Cam sold 9,597 shares of ZNTL for $114,972 on May 31 ’24. The President, Interim CFO now owns 633,680 shares after completing the transaction at $11.98 per share. On May 09 ’24, another insider, HAUSMAN DIANA, who serves as the Chief Medical Officer of the company, sold 3,356 shares for $12.62 each. As a result, the insider received 42,353 and left with 373,876 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 236078320 and an Enterprise Value of -181122448. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.96 while its Price-to-Book (P/B) ratio in mrq is 0.53. Its current Enterprise Value per Revenue stands at -4.466 whereas that against EBITDA is 0.826.
Stock Price History:
Over the past 52 weeks, ZNTL has reached a high of $18.24, while it has fallen to a 52-week low of $2.83. The 50-Day Moving Average of the stock is -15.00%, while the 200-Day Moving Average is calculated to be -67.15%.
Shares Statistics:
According to the various share statistics, ZNTL traded on average about 1.79M shares per day over the past 3-months and 1183680 shares per day over the past 10 days. A total of 70.77M shares are outstanding, with a floating share count of 61.39M. Insiders hold about 13.67% of the company’s shares, while institutions hold 97.56% stake in the company. Shares short for ZNTL as of 1728950400 were 7658786 with a Short Ratio of 4.27, compared to 1726185600 on 11696892. Therefore, it implies a Short% of Shares Outstanding of 7658786 and a Short% of Float of 21.73.
